Published 1 day ago • loading... • Updated 1 day ago

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Summary by WBOC 16

SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE:

+2 Reposted by 2 other sources

SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE:

1 day ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources3

Leaning Left1Leaning Right1Center1Last Updated21 hours agoBias Distribution

34% Left, 33% Center, 33% Right

34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right

34% Left

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

ParrySound.com broke the news 1 day ago on Tuesday, May 26, 2026.

Sources are mostly out of (0)